Effects of rolapitant administered orally on the pharmacokinetics of dextromethorphan (CYP2D6), tolbutamide (CYP2C9), omeprazole (CYP2C19), efavirenz (CYP2B6), and repaglinide (CYP2C8) in healthy subjects

被引：0
|
作者：
Jing Wang
Zhi-Yi Zhang
Sharon Lu
Dan Powers
Vikram Kansra
Xiaodong Wang
机构：
[1] TESARO,
[2] Inc.,undefined
来源：
Supportive Care in Cancer | 2019年 / 27卷
关键词：
Rolapitant; Antiemetics; Neurokinin-1 receptor antagonist; Drug interactions; Cytochrome P450;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：819 / 827
页数：8
相关论文
共 50 条
  • [31] Effect of fifteen CYP3A4 in vitro inducers on the induction of CYP2B6, CYP2C8, CYP2C9, CYP2C19 and CYP3A5 in plated human hepatocytes: a trend analysis
    Zhang, J. George
    Patel, Reena
    Clark, Robert J.
    Ho, Thuy
    Trisdale, Sarah K.
    Stresser, David M.
    DRUG METABOLISM REVIEWS, 2016, 48 : 84 - 84
  • [32] Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers
    Kirchheiner, J
    Meineke, I
    Müller, G
    Roots, L
    Brockmöller, J
    PHARMACOGENETICS, 2002, 12 (07): : 571 - 580
  • [33] Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients
    Lim, Joanne S. L.
    Chen, Xiang A.
    Singh, Onkar
    Yap, Yoon S.
    Ng, Raymond C. H.
    Wong, Nan S.
    Wong, Mabel
    Lee, Edmund J. D.
    Chowbay, Balram
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 71 (05) : 737 - 750
  • [34] The pharmacokinetics of ketobemidone are not affected by CYP2D6 or CYP2C19 phenotype
    Ayman Al-Shurbaji
    Juliette Säwe
    European Journal of Clinical Pharmacology, 2002, 57 : 877 - 881
  • [35] The pharmacokinetics of ketobemidone are not affected by CYP2D6 or CYP2C19 phenotype
    Al-Shurbaji, A
    Säwe, J
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 57 (12) : 877 - 881
  • [36] Pharmacogenetics of ecstasy: CYP1A2, CYP2C19, and CYP2B6 polymorphisms moderate pharmacokinetics of MDMA in healthy subjects
    Vizeli, Patrick
    Schmid, Yasmin
    Prestin, Katharina
    zu Schwabedissen, Henriette E. Meyer
    Liechti, Matthias E.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2017, 27 (03) : 232 - 238
  • [37] Effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide in healthy subjects
    Kang, Pureum
    Cho, Chang-Keun
    Jang, Choon-Gon
    Lee, Seok-Yong
    Lee, Yun Jeong
    Choi, Chang-Ik
    Bae, Jung-Woo
    ARCHIVES OF PHARMACAL RESEARCH, 2023, 46 (05) : 438 - 447
  • [38] Effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide in healthy subjects
    Pureum Kang
    Chang-Keun Cho
    Choon-Gon Jang
    Seok-Yong Lee
    Yun Jeong Lee
    Chang-Ik Choi
    Jung-Woo Bae
    Archives of Pharmacal Research, 2023, 46 : 438 - 447
  • [39] Analysis of CYP2C9*2, CYP2C19*2, and CYP2D6*4 polymorphisms in patients with type 2 diabetes mellitus
    Semiz, Sabina
    Dujic, Tanja
    Ostanek, Barbara
    Prnjavorac, Besim
    Bego, Tamer
    Malenica, Maja
    Marc, Janja
    Causevic, Adlija
    BOSNIAN JOURNAL OF BASIC MEDICAL SCIENCES, 2010, 10 (04) : 287 - 291
  • [40] Genetic Polymorphisms and in Vitro Functional Characterization of CYP2C8, CYP2C9, and CYP2C19 Allelic Variants
    Hiratsuka, Masahiro
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2016, 39 (11) : 1748 - 1759
12345